Ozempic and Finasteride Interaction: What Prescribers and Patients Should Know

Why These Two Drugs Are Increasingly Co-Prescribed

Semaglutide (Ozempic, Wegovy) and finasteride are prescribed together more often than most clinicians expected five years ago. The overlap is straightforward: men aged 35 to 65 with obesity or type 2 diabetes frequently also have androgenetic alopecia or benign prostatic hyperplasia (BPH). Roughly 50% of men over 50 have histologic BPH [1], and the global prevalence of obesity exceeds 650 million adults [2]. These populations overlap substantially.

The Clinical Scenario

A typical co-prescription scenario involves a man in his 40s or 50s starting semaglutide for weight management or glycemic control who already takes finasteride 1 mg for hair loss or 5 mg for BPH. The question that reaches the prescriber or pharmacist: does adding a GLP-1 receptor agonist change how finasteride works, or vice versa?

Why Standard DDI Databases Show Little Data

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not flag a semaglutide-finasteride pair as a meaningful interaction. This absence reflects the pharmacokinetic reality rather than a gap in evidence. The two drugs occupy entirely different metabolic pathways, which the sections below detail.

Pharmacokinetic Analysis: No Meaningful Overlap

Semaglutide is a 31-amino-acid peptide analog of human GLP-1. Its elimination occurs primarily through proteolytic degradation and renal clearance of fragments, not through cytochrome P450 enzymes [3]. The FDA-approved prescribing information for Ozempic states that semaglutide "is not expected to cause drug-drug interactions through effects on CYP enzymes" [3].

Semaglutide Metabolism

Semaglutide has a fatty acid side chain (C-18) that binds albumin, extending its half-life to approximately 7 days. Metabolism involves proteolytic backbone cleavage and sequential beta-oxidation of the fatty acid moiety. CYP450 enzymes play no clinically relevant role in its clearance. Novo Nordisk's population pharmacokinetic analyses across the SUSTAIN trial program confirmed that co-administered medications metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 did not alter semaglutide exposure [3].

Finasteride Metabolism

Finasteride undergoes hepatic metabolism primarily via CYP3A4, with minor contributions from CYP1A2 and CYP2C19 [4]. It is not a P-glycoprotein substrate of clinical relevance. Because semaglutide neither inhibits nor induces CYP3A4, there is no mechanism by which it would alter finasteride plasma concentrations. The reverse is also true: finasteride does not affect peptide degradation or GLP-1 receptor binding.

Gastric Emptying: A Theoretical But Not Practical Concern

Semaglutide slows gastric emptying, which is the basis for its interaction with oral medications that have narrow therapeutic windows (e.g., warfarin, oral contraceptives). For warfarin, the SUSTAIN and PIONEER programs showed small delays in Tmax but no change in AUC or Cmax [3]. Finasteride has high oral bioavailability (approximately 80%), is not pH-sensitive, and has a wide therapeutic index [4]. Slowed gastric transit would not produce clinically meaningful changes in finasteride exposure.

Pharmacodynamic Considerations: Hormonal Intersections

The pharmacodynamic picture deserves more attention than the pharmacokinetic one. Both drugs influence the androgen axis, though through entirely different mechanisms.

Semaglutide and Testosterone

Weight loss itself raises total testosterone in obese men. This is well-documented: adipose tissue expresses aromatase, which converts testosterone to estradiol. Reducing fat mass lowers aromatase activity, raising circulating testosterone. In the STEP 1 trial (N=1,961), participants on semaglutide 2.4 mg lost a mean of 14.9% body weight at 68 weeks versus 2.4% with placebo [5]. Secondary analyses of GLP-1 agonist trials in obese men with hypogonadism have shown total testosterone increases of 100 to 200 ng/dL with 10 to 15% weight loss [6].

Finasteride and Testosterone

Finasteride inhibits type II 5-alpha reductase, blocking the conversion of testosterone to dihydrotestosterone (DHT). This produces a predictable rise in serum testosterone of approximately 10 to 20% and a reduction in serum DHT of 60 to 70% at the 5 mg dose, with proportionally smaller changes at 1 mg [4]. The net hormonal effect is a redistribution within the androgen pathway rather than a suppression of it.

Combined Hormonal Effect

When both drugs are used together, the testosterone-raising effects are additive in direction. A man who loses 30 pounds on semaglutide while taking finasteride may see a larger rise in total testosterone than either intervention would produce alone. This is not dangerous. It is worth noting, however, that rising testosterone may confound PSA monitoring in men on finasteride for BPH. The expected finasteride-induced PSA reduction of approximately 50% at 6 months [7] may be partially offset by testosterone-driven PSA increases from weight loss. Clinicians should document the baseline PSA before starting either drug and re-interpret follow-up values in context.

Sexual Function: Overlapping Adverse-Effect Profiles

Both semaglutide and finasteride have been associated with sexual side effects, though the mechanisms differ.

Finasteride and Sexual Dysfunction

The Prostate Cancer Prevention Trial (PCPT, N=18,882) reported that finasteride 5 mg increased the incidence of sexual adverse events: erectile dysfunction (67.4% vs. 61.5%), reduced libido (65.4% vs. 59.6%), and ejaculatory disorders (5.7% vs. 2.6%) compared with placebo over 7 years [8]. At the 1 mg hair-loss dose, the PLESS extension data and post-marketing surveillance show lower absolute rates, though the signal persists [4].

Semaglutide and Sexual Function

Semaglutide's prescribing information does not list sexual dysfunction as a common adverse event. GLP-1 agonists are not known to directly impair erectile function or libido. Weight loss itself often improves sexual function in obese men. A 2019 meta-analysis in the Journal of Sexual Medicine (14 studies, N=1,316) found that bariatric and pharmacologic weight loss interventions improved IIEF-5 erectile function scores by a mean of 2.8 points [9].

Clinical Implication

The net sexual-function effect of the combination will depend on the individual patient. A man whose erectile dysfunction is primarily obesity-related may experience improvement from semaglutide-mediated weight loss even while taking finasteride. A man whose sexual symptoms are primarily finasteride-driven will not see those symptoms worsen from adding semaglutide. No published data document a synergistic worsening of sexual side effects when these two drugs are combined.

Monitoring Recommendations for Co-Prescribed Patients

No guideline specifically addresses semaglutide-finasteride co-prescribing. The monitoring framework below synthesizes recommendations from the Endocrine Society's 2018 hypogonadism guidelines [10], the AUA's BPH guidelines [1], and the Ozempic prescribing information [3].

Baseline Labs

Before starting both drugs (or adding one to the other), obtain: fasting glucose or HbA1c, lipid panel, total and free testosterone, PSA (if on finasteride 5 mg or if age-appropriate screening applies), and a comprehensive metabolic panel including creatinine and hepatic enzymes.

Follow-Up Schedule

At 3 months, repeat HbA1c (if diabetic), PSA, and testosterone. At 6 months, repeat the full panel. After 12 months of stable co-therapy, annual monitoring is sufficient for most patients. The PSA interpretation requires adjusting for the expected finasteride-induced 50% reduction; any PSA value that rises above the adjusted baseline warrants urologic evaluation regardless of the absolute number [7].

When to Reconsider the Combination

Reconsider the combination if a patient develops new-onset sexual dysfunction after adding the second drug and the symptom is distressing. A trial discontinuation of the more recently added agent (with re-challenge if symptoms resolve) is a reasonable diagnostic approach. Switching finasteride to dutasteride will not resolve the issue, as dutasteride produces similar or more pronounced DHT suppression.

GLP-1 Agonists and CYP3A4 Substrates: Broader Context

Because finasteride is a CYP3A4 substrate, prescribers sometimes extrapolate from GLP-1 warnings about other oral drugs. This extrapolation is not supported.

What the Ozempic Label Actually Says

The Ozempic label recommends caution with oral medications that require rapid absorption for efficacy (specifically mentioning oral contraceptives and antibiotics) due to delayed gastric emptying [3]. It does not list CYP3A4 substrates as a concern. The label explicitly states that population PK analyses found no clinically relevant effect on drugs cleared by CYP3A4.

Liraglutide Precedent

Liraglutide (Victoza/Saxenda), the older GLP-1 agonist, underwent formal interaction studies with multiple CYP3A4 substrates. No clinically significant changes in AUC were observed for atorvastatin, acetaminophen, digoxin, lisinopril, or griseofulvin [11]. These data provide additional class-level reassurance for the GLP-1 agonist/CYP3A4 substrate pairing.

Special Populations

Men With Type 2 Diabetes and BPH

This is the most common co-prescription scenario. Type 2 diabetes accelerates BPH progression through hyperinsulinemia-driven prostatic smooth muscle growth and autonomic nerve dysfunction [12]. Semaglutide addresses the metabolic driver while finasteride addresses the prostatic consequence. The combination is pharmacologically rational and does not require dose modification for either agent.

Younger Men Using Finasteride for Hair Loss

Men aged 25 to 40 using finasteride 1 mg for androgenetic alopecia who start semaglutide (typically off-label for weight management) represent a growing population. The interaction risk is the same as for older men: negligible. The weight-loss-mediated testosterone rise is unlikely to counteract finasteride's hair-preserving effect, because finasteride's mechanism (blocking DHT at the follicle) is independent of total testosterone concentration within the physiologic range [4].

Women

Finasteride is contraindicated in women of childbearing potential due to teratogenicity (FDA Pregnancy Category X) [4]. Semaglutide carries a boxed warning for thyroid C-cell tumors in rodents, and Novo Nordisk recommends discontinuation at least 2 months before planned pregnancy [3]. In the rare clinical scenario where a postmenopausal woman takes both (finasteride off-label for female pattern hair loss, semaglutide for diabetes or weight), the same lack-of-interaction profile applies.

What Patients Should Know

Patients asking "Can I take Ozempic with finasteride?" deserve a direct answer. Yes. No dose change is needed. No special timing is required (though taking finasteride at the same time each day remains good practice regardless of semaglutide use).

Practical Counseling Points

Take finasteride at your usual time. There is no need to separate it from your semaglutide injection day. Report any new sexual symptoms to your prescriber so they can distinguish between a finasteride side effect and an unrelated cause. If you are monitoring PSA, tell your urologist that you are also on semaglutide and have lost weight, because weight loss can independently shift PSA values. Do not stop either medication without consulting your prescriber.